PAVmed Inc.
Close on Oct 19, 2026
- Market cap
- $14.11M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | Before market open | $33.00K | $-0.87 | $-0.27 |
| Q1 FY2026 Ended Mar 31, 2026 | May 15, 2026 | Before market open | $22.00K | $-4.42 | $-1.17 |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 30, 2026 | Before market open | $52.00K | $-2.05 | $-1.05 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | $5.00K | $-0.29 | $-0.02 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | $6.00K | $-0.74 | $-0.05 |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | Before market open | $8.00K | $0.34 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 25, 2025 | Before market open | $10.00K | $0.12 | $-0.06 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | $1.00M | $1.44 | $-0.54 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 15, 2023 | After market close | – | – | – |
Press releases
Announcements PAVmed filed with the SEC
Provides Business Update and Reports Second Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Business Update and Reports First Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities
Material agreement · Agreement terminated · New financial obligation · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
YORK, December 30, 2025 - PAVmed Inc. (NASDAQ: PAVM) (“PAVmed” or the “Company”), a diversified
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Business Update and Reports Third Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Business Update and Reports Second Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Business Update and Reports First Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Business Update and Third Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Efforts to Regain Compliance with Nasdaq Listing Requirements
Acquisition or disposition completed · Listing notice · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
thousands except number of shares and per share data - unaudited)
Acquisition or disposition completed · Listing notice · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Provides Business Update and Second Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Business Update and First Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center – James
Regulation FD disclosure · EX-99.1 to Form 8-K
New York, New York 10017
Other events · EX-99.1 to Form 8-K
Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Business Update and Third Quarter Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Business Update and Preliminary Fourth Quarter and Full Year 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Holds First #CheckYourFoodTube Precancer Testing Event
Regulation FD disclosure · EX-99.1 to Form 8-K
and Lucid Diagnostics Provide Strategic Business Update
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Third Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Business Update and Preliminary Second Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Business Update and Preliminary First Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
THE COURT OF CHANCERY OF THE STATE OF DELAWARE
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Procedural Update on its Settlement of a Previously Disclosed Class Action Lawsuit
Regulation FD disclosure · EX-99.2 to Form 8-K
Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
to Hold a Business Update Conference Call on March 29, 2022
Regulation FD disclosure · EX-99.1 to Form 8-K
PAVmed Appoints Shaun O’Neil as Chief Operating
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Executive and Healthcare Services Industry Leader Joan Harvey Named to PAVmed Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
and Lucid to Hold Joint Business Update Conference Call on November 16, 2021
Results of operations · EX-99.1 to Form 8-K
Digital Health Subsidiary Veris Health Appoints Sunny Webb as Chief Technology Officer
Regulation FD disclosure · EX-99.1 to Form 8-K
Acquires EsophaCap Manufacturer CapNostics LLC
Other events · EX-99.1 to Form 8-K